Cancer Immunotherapy: Beyond Immune Checkpoint Blockade and Overcoming Resistance (C2)
March 17-20, 2024
| Fairmont Chateau Whistler, Whistler, BC, Canada
James P. Allison, Andrea Schietinger, Antoni Ribas and Padmanee Sharma
Scholarship Deadline: Dec. 7, 2023 | Abstract Deadline: Dec. 7, 2023 | Early Registration Deadline: Jan. 17, 2024
| 4:00–8:00 PM |
Registration |
Macdonald Foyer |
| 6:00–8:00 PM |
Welcome Mixer |
Macdonald Foyer |
| 7:00–8:00 AM |
Breakfast |
MacDonald CDEF |
| 8:00–9:00 AM |
Welcome and Keynote Address |
Macdonald AB |
| |
James P. Allison, University of Texas MD Anderson Cancer Center
Immune Checkpoint Blockade in Cancer Therapy: New Insights into Therapeutic Mechanisms of anti-CTLA4 and anti-PD-1 |
|
| 9:00–11:15 AM |
Clinical Trials to Identify Mechanisms of Response and Resistance |
Macdonald AB |
| |
Andrea Cercek, Memorial Sloan Kettering Cancer Center
Single Agent PD-1 Blockade as Curative-Intent Treatment in Mismatch Repair Deficient Locally Advanced Rectal Cancer |
|
| 9:30–9:50 AM |
Coffee Break |
Macdonald Foyer |
| 11:15–1:00 PM |
Poster Setup |
MacDonald CDEF |
| 11:15–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
MacDonald CDEF |
| 2:30–4:30 PM |
Panel Discussion on Failed Trials |
Macdonald AB |
| |
Antoni Ribas, University of California, Los Angeles
Role of IFN-gamma in Response and Resistance to Cancer Immunotherapies |
|
| |
Padmanee Sharma, University of Texas MD Anderson Cancer Center
Neoadjuvant and Tissue-based Trials for Evaluating Mechanisms of Response and Resistance |
|
| |
Georgina V. Long, Melanoma Institute Australia, The University of Sydney
Neoadjuvant Therapy: Where We Have Come from and Where to Next |
|
| 4:30–5:00 PM |
Coffee Available |
Macdonald Foyer |
| 5:00–7:00 PM |
Regulation of Immune Responses by Myeloid Cells, Dendritic Cells and Tertiary Lymphoid Structures |
Macdonald AB |
| |
Miriam Merad, Mount Sinai School of Medicine
Molecular and Spatial Correlates of Response to PD-1 Blockade in Human Tumors |
|
| |
Haydn Kissick, Emory University
A Stem-Like CD4 T Cell Controls Immunity to Cancer |
|
| |
Gabriel A. Rabinovich, Instituto de Biologia y Medicina Experimental
Galectins: Emerging Glyco-Checkpoints in the Tumor Microenvironment |
|
| |
Teresa Dinter, MIT
Short Talk: Short Talk: The Signal Strength of Signal 2 and 3 During T Cell Priming Affect the Functional Fate of an Anti-tumor T Cell Response |
|
| |
Anna Juncker-Jensen, NeoGenomics
Short Talk: Short Talk: Spatial Relationship of Tertiary Lymphoid Structures and Neutrophils in Bladder Cancer and Prognostic Potential for PD-L1 Immunotherapy |
|
| |
Jyh Liang Hor, National Institutes of Health
Short Talk: Short Talk: PD-1/cDC1 Axis in the Tumor Draining Lymph Node Regulates Stem-like CD8+ T Cell Differentiation |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
MacDonald CDEF |
| 7:30–10:00 PM |
Poster Session 1 |
MacDonald CDEF |
| |
Ruozhen Hu, Genentech
Anti-TIGIT Antibody Tiragolumab Leverages Myeloid Cells and Regulatory T Cells to Improve PD-L1 Checkpoint Blockade |
|
| |
Kelsey E. Sivick Gauthier †, Arcus Biosciences, Inc.
Fc-silent anti-TIGIT Antibodies Offer Best-in-class Potential by Potentiating Robust CD8+ T Cell Mediated Anti-tumor Immunity Without Peripheral Regulatory T Cell Depletion |
|
| |
Zoya Alteber, Compugen Ltd.
PVRIG is Uniquely Expressed in Tumor Dendritic Cell-rich Niches on Stem-like Memory T Cells and its Blockade May Induce Immune Infiltration and Activation in Non-inflamed Tumors |
|
| |
Thierry Guillaudeux, Kineta, Inc
VISTA-101 – An Ongoing Phase 1/2 Clinical Trial of KVA12123 Targeting VISTA, Alone and in Combination with Pembrolizumab in Advanced Solid Tumors |
|
| |
Edward van der Horst, Sensei Biotherapeutics
VISTA Checkpoint Targeting by SNS-101, a pH-selective Antibody with Enhanced Safety and Pharmacokinetic Profiles, Alters the Tumor Microenvironment and Overcomes Immune Checkpoint Inhibitor Resistance |
|
| 7:00–8:00 AM |
Breakfast |
MacDonald CDEF |
| 8:00–11:00 AM |
Novel Insights into T Cell Biology |
Macdonald AB |
| |
Andrea Schietinger, Memorial Sloan Kettering Cancer Center
Talk Title to be Announced |
|
| |
Laura Codari Deak, Roche Innovation Center Zurich
PD-1 + IL-2 to Drive Differentiation of Effector T Cells in Tumor |
|
| |
colli Agudo, Dana-Farber Cancer Institute
Uncovering Hidden Drivers of Immune Evasion: Stemness and Cell Cycle |
|
| |
Marcus Bosenberg, Yale University
Short Talk: Short Talk: Epigenetically Poised IL-7R+ CD8+ T Cells are Critical for Anti-melanoma Memory |
|
| |
Assaf Menachem, Compugen
Short Talk: Short Talk: Unleashing Natural IL-18 Activity Using an Anti-IL-18BP Blocker Antibody Induces Potent Immune Stimulation and Anti-tumor Effects |
|
| |
Judit Díaz Gómez, Vall d'Hebron Institute of Oncology
Short Talk: Short Talk: Unravelling Tumor-intrinsic Resistance Mechanisms to T-cell Mediated Cytotoxicity in Pancreatic Cancer |
|
| |
Jacqueline Yee, University of California, San Francisco
Short Talk: Short Talk: CD40 Agonist Systemically Drives the Expansion of Tumor-Specific CD8 T Cells into a PD1+ KLRG1+ Effector State |
|
| 9:00–9:20 AM |
Coffee Break |
Macdonald Foyer |
| 11:00–1:00 PM |
Poster Setup |
MacDonald CDEF |
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–2:00 PM |
Career Roundtable |
Macdonald AB |
| |
Alena Gros, Vall d'Hebron Institute of Oncology
Group Leader of VHIO´s Tumor Immunology and Immunotherapy Group |
|
| |
Andrea Cercek, Memorial Sloan Kettering Cancer Center
Associate Attending Physician |
|
| |
Edward van der Horst, Sensei Biotherapeutics
Chief Scientific Officer |
|
| |
jed Gameiro, National Cancer Institute
Staff Scientist and Head of the Molecular Immunology Group of the Center for Immuno-Oncology, NCI |
|
| 1:00–10:00 PM |
Poster Viewing |
MacDonald CDEF |
| 4:30–5:00 PM |
Coffee Available |
Macdonald Foyer |
| 5:00–7:00 PM |
Understanding Spatial Temporal Interactions Guiding Response and Resistance in the Tumor and Lymph Nodes |
Macdonald AB |
| |
Ronald N. Germain, NIAID, National Institutes of Health
Gaining Insight into Tumor Immunity by Combining New Highly Multiplex 2D and 3D Imaging with Analytical Tools |
|
| |
Garry P. Nolan, Stanford University
Immune Pathology from the Subcellular Scale on Up |
|
| |
Brian D. Brown, Mount Sinai School of Medicine
Spatial CRISPR |
|
| |
Soki Kashima, Yale Cancer Center, Yale School of Medicine
Short Talk: Short Talk: Exploring Resistance Mechanisms to Immune Checkpoint Inhibitor-based Therapies through Single-cell Analysis of Renal Cell Carcinoma |
|
| |
Katie Campbell, University of California, Los Angeles
Short Talk: Short Talk: Mature Endothelial Vessels Facilitate Tumor-infiltration by Checkpoint Positive T Cells Following Ipilimumab in Anti-PD-1-resistant Tumors |
|
| 7:00–8:00 PM |
Social Hour with Lite Bites |
MacDonald CDEF |
| 7:30–10:00 PM |
Poster Session 2 |
MacDonald CDEF |
Wednesday, March 20, 2024
| |
Alexander Keller, EPFL
Catalytically Inactive cGAS Potentiates Antitumor Immunity |
|
| |
Klaus Heger, Genentech, Inc
The Exonuclease TREX1 Constitutes an Innate Immune Checkpoint Limiting cGAS/STING-Mediated Anti-tumor Immunity |
|
| |
Eric Collisson †, University of California San Francisco
Leukemia Inhibitory Factor Fosters Immune Evasion in KRAS-driven Pancreatic Ductal Adenocarcinoma |
|
| |
Jordan J. Cardenas, Yale University
Modified IL-18 Combined with Anti-PD1 Elicits a CD4+ T Cell-mediated Antitumor Response in MHC Class I-deficient Models of Non-small Cell Lung Cancer |
|
| |
Joan Seoane, Vall d'Hebron Institute of Oncology; Vall d'Hebron University Hospital
C1q Impairs the Response to Immunotherapies in Glioblastoma |
|
| |
Hideho Okada, University of California, San Francisco
Glioma-neuronal Circuit Remodeling Induces Regional Immunosuppression |
|
| |
Kok Haw Jonathan Lim, The Francis Crick Institute
The Dendritic Cell Receptor DNGR-1 Couples Dead Cell Sensing to Cancer Immunoediting |
|
| |
Emanuel Salazar Cavazos, National Cancer Institute / National Institutes of Health
Stochasticity in Cancer Immunotherapy Maps with the Rarity of Critical Spark T Cells |
|
| 7:00–8:00 AM |
Breakfast |
MacDonald CDEF |
| 8:00–11:00 AM |
Engineering T Cells to Overcome Immune Resistance |
Macdonald AB |
| |
Yvonne Y. Chen, University of California, Los Angeles
Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy |
|
| |
Avery D. Posey, University of Pennsylvania
Chimeric Antigen Receptor T-Cells and Carbohydrate-Based Cancer Targets |
|
| |
Justin Eyquem, University of California, San Francisco
Synthetic Immunology and Genome Editing Tools to Advance T Cell Therapies |
|
| |
Yuta Asano, Fred Hutchinson Cancer Center
Short Talk: Short Talk: Delayed Tumor Regression Following TCR-T, Anti-PD-L1 and IFNγ Combination Therapy in a Patient with Checkpoint Blockade-refractory HLA-downregulated Merkel Cell Carcinoma |
|
| |
Ian A. Parish, Peter MacCallum Cancer Centre
Short Talk: Short Talk: Ikaros Family Transcription Factors Cooperatively Enforce T Cell Exhaustion and Restrain CAR T Cell Efficacy |
|
| |
Angela C. Boroughs, ArsenalBio
Short Talk: Short Talk: Mapping CAR and TCR T Cell Exhaustion through Combinatorial CRISPR Screens |
|
| |
Carli Stewart, Mayo Clinic Graduate School of Biomedical Sciences
Short Talk: Short Talk: Uncovering a Novel Role for IL-4 in the Development of CART Cell Exhaustion |
|
| 9:00–9:20 AM |
Coffee Break |
Macdonald Foyer |
| 11:00–1:00 PM |
Poster Setup |
MacDonald CDEF |
| 11:00–5:00 PM |
On Own for Lunch |
|
| 1:00–10:00 PM |
Poster Viewing |
MacDonald CDEF |
| 4:30–5:00 PM |
Coffee Available |
Macdonald Foyer |
| 5:00–6:45 PM |
Tumor Antigens and Cancer Vaccines |
Macdonald AB |
| |
Alena Gros, Vall d'Hebron Institute of Oncology
Neoantigen Targeting with Tumor Infiltrating Lymphocytes |
|
| |
Thamizhanban Manoharan, National University of Singapore
Short Talk: Short Talk: Exploring the Potential use of Alternate Neoantigens for the Generation of Therapeutic Cancer Vaccines to Improve Efficacy of Immune Checkpoint Blockade |
|
| |
Matthew Gubin, MD Anderson
Short Talk: Short Talk: Overlapping and Distinct Mechanisms of Effective Neoantigen Cancer Vaccines and Immune Checkpoint Therapy |
|
| |
Sangeeta Goswami, MD Anderson Cancer Center
Histone Lactylation(s) Orchestrate Epigenetic and Transcriptional Networks Driving CD8 T Function |
|
| 6:45–7:00 PM |
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
Macdonald AB |
| 7:00–8:00 PM |
Social Hour with Lite Bites |
MacDonald CDEF |
| 7:30–10:00 PM |
Poster Session 3 |
MacDonald CDEF |
